1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Patient Assistance Programs: Payer and Pharma Perspectives




Patient assistance programs (PAPs) are evolving in response to increasingly restrictive formularies and payer criticism. Patient Assistance Programs: Payer and Pharma Perspectives is a report that gives unique insight into payer attitudes and opinions on the future of PAPs.

As the numbers grow for Americans without private health insurance, the answer for many has been patient assistant programs. But as the pharmaceutical industry moved towards co-pay and coupon models, payers have been increasingly resistant and critical of the new PAP schemes.

FirstWord’s Patient Assistance Programs: Payer and Pharma Perspectives report offers an insightful and thorough examination of the current PAP environment, evaluating payer moods, attitudes and strategies.

Based on in-depth interviews with national payers and pharmaceutical industry experts, the report is an important tool for finding the optimal strategy and approach to the development and implementation of PAPs.







Key Takeaways

Gain insight into payer attitudes and strategies regarding the true cost of PAPs to the healthcare system
Learn which factors influence payer decision making when it comes to supporting PAPs and how that can be leveraged
Discover when pharma should engage with payers in the development and implementation of PAPS
Learn payer attitudes on a range of key issues, including the value of measuring PAP impact on patient adherence and health outcomes
Gain insight into how payers and industry experts predict PAPs will change in the future

Get Answers to Critical Questions

What factors would positively influence payer attitudes towards PAPs?
As formularies become more restrictive, what does the future hold for PAPs?
What do payers predict will happen with regards regulating PAPs?
What are the key drivers of distrust among payers over PAPs and how can this be reversed?
What can be done to increase data capture to improve quality of care?
What is the industry view of PAPs, and how does this compare with the views of payers?

Key Features

Insight into payer criticisms and opinions on issues such as PAPs as ‘backdoor’ route to market access, ensuring product uptake and a mechanism for maintaining high prices
Overview of different types of patient assistant programs across the US
Examination of the key drivers in PAP development and implementation
Key findings into the role of PAPs as essential mechanisms in maintaining competitiveness
Recommendations by payers to increase flexible and ongoing interaction with pharmaceutical companies

Expert Contributors

Pharmacy director, government health plan
Pharmacy director, national health insurer
Executive Vice President of a national Pharmacy Benefits Manager (PBM)
Chief Medical Officer, Managed Care Organisation
Health plan medical director
Medical director at global level for a major pharmaceutical company
Health Outcomes director at a US affiliate for a top pharmaceutical company

Key Quotes from Contributors
“Years ago, patient assistance program means programs that help out patients who were below a certain level on the poverty line, because they couldn't afford their medications. Now patient assistance program means I don't care what tier my drug is on, I'm going to give somebody a co-pay card so they can get my drug irrespective of how the payer is handling those drugs.”
Pharmacy Director, government health plan


“My goal if somebody needs an oral oncology drug is not to have them take $2,500 out of their bank accounts for them to get the drug. My argument with the manufacturer would be don't charge $100,000 for the drug and stop giving away $2,500 coupons.”
Chief Medical Officer

“It doesn't make me feel anything if they don't show a willingness to change the programme and work with me on something. If they just want to keep running the programme and ramming it down my throat, I feel pretty bad about that. If they want to work and look at a collaborative approach, it makes me feel a lot better.”
Executive Vice President PBM


“I think that these kinds of assistance programs, from the company's perspective, they realise are critical in terms of maintaining trust with the regulators and maintaining trust for the patient. They know that there has to be a fine balance between making sure people get access to the drugs, especially in countries which contributed the development of the drug.”
Global Medical Director, major pharmaceutical company.



Table Of Contents

Patient Assistance Programs: Payer and Pharma Perspectives
1.Executive summary
1.1.PAPs were originally recognised as a charitable move by industry to provide access for needy patients
1.2.The introduction of co-payment cards changed the way in whichPAPs are perceived by payers
1.3.Payer engagement in the development of PAPs is limited
1.4.PAPs that deliver on outcomes will be favoured in the future

2.Research objectives and methodology
3.Patient Assistance Programs overview
3.1.What are patient assistance programs?
3.1.1.Why are patient assistance programs needed?
3.2.Different types of patient assistance programs
3.2.1.Non-industry patient assistance programs
3.2.2.Eligibility and enrolment requirements
4.Payer opinions on Patient Assistance Programs
4.1.Payers recognise PAPs deliver benefits to those patients in financial need
4.1.2.The high cost of specialist products means patient assistance
is often necessary
4.1.2.Payers are concerned about patients who would
“fall between the gaps” without PAPs
4.2.Payers have several concerns with patient assistance programs
4.2.1.A key criticism is that PAPs are being used to avoid formulary restrictions
4.2.1.1.Sampling is also seen in a negative light
4.2.1.2.Some payers are concerned that patients are being misled by PAPs
4.2.1.3Some payers feel that, in the longer term, PAPs are more costly for the health system
4.3.Payers are cynical as to the genuine reasons for PAPs
4.3.1.PAPs are seen as a way to ensure product uptake
4.3.2.Several payers believe PAPs are a “backdoor” route to market access
4.3.3.PAPs are also viewed as a mechanism of maintaining inflated prices
5.Industry opinions on Patient Assistance Programs
5.1.There are a number of key benefits that pharmaceutical companies gain from PAPs
5.1.2Ensuring widespread patient access to drugs is a fundamental reason
for implementing PAPs
5.1.3.PAPs are now seen as essential in order to maintain competitiveness
in increasingly crowded markets.
5.1.4.The patient benefits that PAPs deliver are also a driver for industry
5.1.4.1.Compliance is a driver for industry - but for different reasons to payers
5.2.The use of products that would otherwise be limited is seen as the
payers' key objection by industry
5.3.Patient and competitive benefit are seen as the main reasons for
pharmaceutical companies running PAPs
6.Payer-pharma engagement
6.1.Payers have limited decision-making responsibilities for PAPs
6.2.Pharmaceutical companies will inform payers of their planned PAPs
6.3.Payers need a basic range of information about PAPs
6.4.Flexible and ongoing interaction would be useful for payers
6.4.1.PAPs that provide information on outcomes would be favoured
7.Future outlook
7.1.The numbers of PAPs, and patients accessing them,
is expected to continue to grow
7.2.Payers expect a rise in regulation around PAPs
7.3.Continued distrust of PAPs will be the main challenge faced by manufacturers
7.4.Payers expect the management of PAPs to become more challenging
7.4.1.The provision and analysis of data and outcomes is vital for payers
7.5.Industry also expects PAPs to change in the future
8.Contributors

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.